Octreotide

380 interactions 555 cited references

Also sold as: Bynfezia Mycapssa Mycapssa® Sandostatin

About Octreotide

Octreotide is used to treat acromegaly (condition in which the body produces too much growth hormone, causing enlargement of the hands, feet, and facial features; joint pain; and other symptoms) in people who have been treated successfully with octreotide injection (Sandostatin) or lanreotide injection (Somatuline). Oc… Read the full Octreotide drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Terfenadine Piperaquine Pimozide Saquinavir Sparfloxacin Thioridazine

13 Contraindicated 363 Major 4 Moderate

All (380) Contraindicated (13) Major (363) Moderate (4)

Contraindicated

Octreotide Bepridil An increased risk of QT interval prolongation Details Octreotide Cisapride Propulsid® Increased risk of QT interval prolongation Details Octreotide Dronedarone Multaq Increased risk of QT interval prolongation Details Octreotide Levoketoconazole Recorlev An increased risk of QT interval prolongation and an increased risk of torsade de pointes Details Octreotide Levomethadyl An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Mesoridazine An increased risk of QT interval prolongation Details Octreotide Pimozide An increased risk of QT interval prolongation Details Octreotide Piperaquine An increased risk of QT interval prolongation Details Octreotide Saquinavir An increased risk of QT interval prolongation Details Octreotide Sparfloxacin An increased risk of QT interval prolongation Details Octreotide Terfenadine An increased risk of QT interval prolongation Details Octreotide Thioridazine An increased risk of QT interval prolongation Details Octreotide Ziprasidone Geodon An increased risk of QT interval prolongation Details

Major

Octreotide Clindamycin ANTIROBE Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Omeprazole Gastrobim Decreased octreotide bioavailability Details Octreotide Amitriptyline Elavil An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Sertraline An increased risk of QT interval prolongation Details Octreotide Buprenorphine Belbuca An increased risk of QT interval prolongation Details Octreotide Relugolix Orgovyx Increased risk of QT interval prolongation Details Octreotide Colchicine Colcrys Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Abemaciclib Verzenio Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Acalabrutinib Calquence Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Amisulpride Injection Barhemsys Increased risk of serious ventricular arrhythmias such as torsades de pointes Details Octreotide Arsenic Trioxide Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Aripiprazole Injection Abilify An increased risk of QT interval prolongation Details Octreotide Arsenic Trioxide Injection Trisenox An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Asenapine Transdermal Patch Secuado Increased risk of QT interval prolongation Details Octreotide Azithromycin AzaSite An increased risk of QT interval prolongation Details Octreotide Anagrelide Agrylin Increased risk of QT interval prolongation Details Octreotide Axitinib Inlyta Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Bedaquiline Sirturo Increased risk of QT interval prolongation Details Octreotide Bosutinib Bosulif Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Brigatinib Alunbrig Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Chloroquine Aralen® An increased risk of cardiotoxicity (QT prolongation, torsades de pointes, cardiac arrest) Details Octreotide Clindamycin Injection ANTIROBE Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Clindamycin Topical C/T/S® Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Clindamycin Vaginal Cleocin Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Cobimetinib Cotellic Increased exposure of CYP3A4 substrates with narrow therapeutic index Details Octreotide Cyclosporine Injection Atopica Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details Octreotide Cyclosporine Ophthalmic Cequa Reduced cycloSPORINE exposure and reduced efficacy of cycloSPORINE Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.